- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 13 - Final Insights
During the conclusion of this panel discussion, the panelists provide their final insights about managed care’s role in castration-resistant prostate cancer (CRPC).
E. David Crawford, MD, explains that as agents continue to develop for the treatment of CRPC, there is a need to better evaluate their roles. He explains that managed care needs to assess which factors are most important to patients and third-party payers.
Michael Kolodziej, MD, explains that although CRPC has entered an exciting era, there are many outstanding challenges that need to be addressed.
Jeffrey D. Dunn, PharmD, MBA, believes that managed care needs to focus on cost trends, address payment reform, invest in information technology, and improve coordination between stakeholders.
David Quinn, MD, suggests that achieving the primary goal of improving care for patients with CRPC begins with a commitment by managed care. He explains that managed care needs to determine which treatment options are the most cost-effective.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization
March 7th 2025A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.
Read More
